Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS-2: copanlisib versus placebo in rituximab-refractory indolent non-Hodgkin lymphoma
2014-000925-19Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in indolent lymphoma comparing Copanlisib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Feb 2015; status: completed.
02
Drugs
copanlisib
03
Conditions
indolent lymphoma
Beyond the preview
Go deeper on 2014-000925-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000925-19.